JP2016517960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517960A5 JP2016517960A5 JP2016506682A JP2016506682A JP2016517960A5 JP 2016517960 A5 JP2016517960 A5 JP 2016517960A5 JP 2016506682 A JP2016506682 A JP 2016506682A JP 2016506682 A JP2016506682 A JP 2016506682A JP 2016517960 A5 JP2016517960 A5 JP 2016517960A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- amount
- her2
- total
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 235
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 235
- 206010028980 Neoplasm Diseases 0.000 claims description 109
- 239000000523 sample Substances 0.000 claims description 98
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 79
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 60
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 36
- 108091007960 PI3Ks Proteins 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 35
- 230000008685 targeting Effects 0.000 claims description 30
- 239000000833 heterodimer Substances 0.000 claims description 28
- 238000003776 cleavage reaction Methods 0.000 claims description 24
- 230000007017 scission Effects 0.000 claims description 24
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000026731 phosphorylation Effects 0.000 claims description 10
- 238000006366 phosphorylation reaction Methods 0.000 claims description 10
- 229950008835 neratinib Drugs 0.000 claims description 8
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 6
- 238000011278 co-treatment Methods 0.000 claims description 6
- 229960002087 pertuzumab Drugs 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 5
- QSUPQMGDXOHVLK-FFXKMJQXSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 QSUPQMGDXOHVLK-FFXKMJQXSA-N 0.000 claims description 4
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 claims description 4
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 229960001686 afatinib Drugs 0.000 claims description 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- JXLVPHOTGHZUCE-ZSIUJALASA-N methyl n-[4-[5-chloro-2-[(1s)-1-[[(e)-3-[5-chloro-2-(tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-3-morpholin-4-yl-3-oxopropyl]-1h-imidazol-4-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=C(Cl)NC([C@H](CC(=O)N2CCOCC2)NC(=O)\C=C\C=2C(=CC=C(Cl)C=2)N2N=NN=C2)=N1 JXLVPHOTGHZUCE-ZSIUJALASA-N 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000004850 protein–protein interaction Effects 0.000 claims description 2
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 238000011262 co‐therapy Methods 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 239000000710 homodimer Substances 0.000 description 4
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809083P | 2013-04-05 | 2013-04-05 | |
| US61/809,083 | 2013-04-05 | ||
| PCT/US2014/033208 WO2014165855A1 (en) | 2013-04-05 | 2014-04-07 | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517960A JP2016517960A (ja) | 2016-06-20 |
| JP2016517960A5 true JP2016517960A5 (OSRAM) | 2017-03-30 |
| JP6402173B2 JP6402173B2 (ja) | 2018-10-10 |
Family
ID=50686216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506682A Expired - Fee Related JP6402173B2 (ja) | 2013-04-05 | 2014-04-07 | Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160041171A1 (OSRAM) |
| EP (1) | EP2981828A1 (OSRAM) |
| JP (1) | JP6402173B2 (OSRAM) |
| CN (1) | CN105264382A (OSRAM) |
| CA (1) | CA2908515A1 (OSRAM) |
| WO (1) | WO2014165855A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2816624T3 (es) | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
| RS66392B1 (sr) | 2014-02-28 | 2025-02-28 | Merus Nv | Antitelo koje vezuje erbb-2 i erbb-3 |
| WO2016127220A1 (en) * | 2015-02-13 | 2016-08-18 | The University Of Queensland | Methods for classifying tumors and uses therefor |
| US11939394B2 (en) | 2015-10-23 | 2024-03-26 | Merus N.V. | Binding molecules that inhibit cancer growth |
| JP2019515252A (ja) * | 2016-03-15 | 2019-06-06 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | 細胞間のタンパク質相互作用を評価する方法 |
| KR20190015360A (ko) * | 2016-05-31 | 2019-02-13 | 네스텍 소시에테아노님 | Ｈｅｒ2 및 ｈｅｒ3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법 |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| KR20180117529A (ko) * | 2017-04-19 | 2018-10-29 | 주식회사 프로티나 | 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법 |
| EP3625264B9 (en) | 2017-05-17 | 2023-10-25 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| EP3807640A4 (en) * | 2018-06-14 | 2022-04-13 | Memorial Sloan Kettering Cancer Center | METHODS FOR PREDICTING RESPONSIVENESS OF LUNG CANCER PATIENTS TO HER2-TARGETING THERAPIES |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4318846A (en) | 1979-09-07 | 1982-03-09 | Syva Company | Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| WO1989012232A1 (en) | 1988-06-08 | 1989-12-14 | London Diagnostics, Inc. | Assays utilizing sensitizer-induced production of detectable signals |
| US4997928A (en) | 1988-09-15 | 1991-03-05 | E. I. Du Pont De Nemours And Company | Fluorescent reagents for the preparation of 5'-tagged oligonucleotides |
| US5654442A (en) | 1989-11-14 | 1997-08-05 | The Perkin-Elmer Corporation | 4,7-dichlorofluorescein dyes as molecular probes |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| EP0484027B1 (en) | 1990-11-02 | 1996-12-18 | Zeneca Limited | Polysubstituted phthalocyanines |
| JP2758730B2 (ja) | 1991-04-25 | 1998-05-28 | 三菱電機株式会社 | 放電励起パルスレーザ発振装置 |
| US5340716A (en) | 1991-06-20 | 1994-08-23 | Snytex (U.S.A.) Inc. | Assay method utilizing photoactivated chemiluminescent label |
| US5578498A (en) | 1991-05-22 | 1996-11-26 | Behringwerke Ag | Metal chelate containing compositions for use in chemiluminescent assays |
| US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| DE69334053T2 (de) | 1992-04-10 | 2007-01-04 | Dana-Farber Cancer Institute, Inc., Boston | Immunnachweis eines aktivierungszustandsspezifischen phosphoproteins |
| ATE162892T1 (de) | 1992-07-31 | 1998-02-15 | Behringwerke Ag | Photoaktivierbare chemiluminizierende matrices |
| US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5986076A (en) | 1994-05-11 | 1999-11-16 | Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US5945526A (en) | 1996-05-03 | 1999-08-31 | Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
| US5763602A (en) | 1996-10-01 | 1998-06-09 | Li; Ying-Syi | Methods of syntheses of phthalocyanine compounds |
| US6001673A (en) | 1999-02-11 | 1999-12-14 | Ericsson Inc. | Methods for packaging integrated circuit devices including cavities adjacent active regions |
| US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US6191278B1 (en) | 1999-11-03 | 2001-02-20 | Pe Corporation | Water-soluble rhodamine dyes and conjugates thereof |
| US6372907B1 (en) | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
| US6346384B1 (en) | 2000-03-27 | 2002-02-12 | Dade Behring Inc. | Real-time monitoring of PCR using LOCI |
| US20030170734A1 (en) | 2000-04-28 | 2003-09-11 | Stephen Williams | Multiplexed assays using electrophoretically separated molecular tags |
| JP4796259B2 (ja) | 2000-05-04 | 2011-10-19 | シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー | 複数のアナライトの検出において使用するための組成物 |
| US6547654B2 (en) | 2000-07-22 | 2003-04-15 | Americo Del Raso | Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander |
| KR20040082273A (ko) | 2001-05-21 | 2004-09-24 | 아클라라 바이오사이언시스 인코퍼레이티드 | 단백질 분석을 위한 방법 및 조성물 |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| AU2002357309A1 (en) | 2001-12-18 | 2003-06-30 | Aclara Biosciences, Inc. | Photoactivation device and method |
| JP2006509183A (ja) | 2002-03-05 | 2006-03-16 | アクララ バイオサイエンシーズ， インコーポレイテッド | 膜結合増感剤を用いる多重分析 |
| US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| ATE535254T1 (de) * | 2002-07-15 | 2011-12-15 | Genentech Inc | Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4 |
| ES2332310T3 (es) | 2002-07-25 | 2010-02-02 | Aclara Biosciences, Inc. | Deteccion de oligomerizacion de receptor. |
| BRPI0408950A (pt) * | 2003-04-01 | 2006-03-28 | Monogram Biosciences Inc | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
| EP2215251A2 (en) * | 2007-11-30 | 2010-08-11 | Siemens Healthcare Diagnostics GmbH | Method for predicting therapy responsiveness in basal like tumors |
| EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| JP2012515353A (ja) * | 2009-01-15 | 2012-07-05 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
| JP5746051B2 (ja) * | 2009-01-15 | 2015-07-08 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｈｅｒ−３の測定による患者の反応を判定する方法 |
| WO2013033623A1 (en) * | 2011-09-02 | 2013-03-07 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| CN102492039B (zh) * | 2011-11-21 | 2015-03-11 | 无锡天演生物技术有限公司 | 全人源抗人her2单抗 |
-
2014
- 2014-04-07 JP JP2016506682A patent/JP6402173B2/ja not_active Expired - Fee Related
- 2014-04-07 US US14/781,468 patent/US20160041171A1/en not_active Abandoned
- 2014-04-07 EP EP14722931.4A patent/EP2981828A1/en not_active Withdrawn
- 2014-04-07 WO PCT/US2014/033208 patent/WO2014165855A1/en not_active Ceased
- 2014-04-07 CN CN201480030240.4A patent/CN105264382A/zh active Pending
- 2014-04-07 CA CA2908515A patent/CA2908515A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517960A5 (OSRAM) | ||
| Takenaka et al. | Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysis | |
| Parseghian et al. | Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge | |
| JP2012515226A5 (OSRAM) | ||
| Yan et al. | HER2 aberrations in cancer: implications for therapy | |
| Mar et al. | Targeting HER2 in the treatment of non-small cell lung cancer | |
| Bianchini et al. | Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer | |
| ES2687783T3 (es) | Biomarcadores de cáncer y usos de los mismos | |
| Fugazzola et al. | Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment | |
| Olivotto et al. | Time to stop progesterone receptor testing in breast cancer management | |
| JP2014074724A5 (OSRAM) | ||
| JP5963005B2 (ja) | 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー | |
| CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
| US20130183303A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| González-Santiago et al. | Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study) | |
| Lee et al. | Detection of ERBB2 (HER2) gene amplification events in cell-free DNA and response to anti-HER2 agents in a large asian cancer patient cohort | |
| Tota et al. | Lung cancer screening: review and performance comparison under different risk scenarios | |
| JP2015527055A (ja) | 細胞全体でのアッセイおよび方法 | |
| KR20130055647A (ko) | 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법 | |
| Oh et al. | Clinical activity of pan-HER inhibitors against HER2-mutant lung adenocarcinoma | |
| JP2017501137A5 (OSRAM) | ||
| JP2018523105A5 (OSRAM) | ||
| JP2016014671A (ja) | 抗癌治療への応答可能性の増大した患者を同定する方法 | |
| Nyström et al. | Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement | |
| Miceli et al. | [18F] FDG PET/CT criteria for treatment response assessment: EORTC and beyond |